Almirall SA
MAD:ALM
Relative Value
The Relative Value of one
ALM
stock under the Base Case scenario is
12.81
EUR.
Compared to the current market price of 13.76 EUR,
Almirall SA
is
Overvalued by 7%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ALM Competitors Multiples
Almirall SA Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Almirall SA
MAD:ALM
|
3B EUR | 1.9 | 53.2 | 11.1 | 25.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD | 14.7 | 46.5 | 31.3 | 33.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF | 4.8 | 31.1 | 13.1 | 15.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP | 5.5 | 31.6 | 17.4 | 24.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF | 5.5 | 22.2 | 13.7 | 17.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD | 4.7 | 16.7 | 10.4 | 12.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.3 | 13 | 9.5 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD | 2.4 | 19.5 | 7.3 | 9.7 | |
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR | 2.8 | 15.8 | 8 | 11.3 |